Johnson K S Lam1,2, Puma Sundaresan1,3, Val Gebski1,4, Michael J Veness1,3. 1. Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia. 2. Department of Radiation Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford, Australia. 3. Sydney Medical School, University of Sydney, Sydney, Australia. 4. National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, Australia.
Abstract
BACKGROUND: Immunocompromised patients with metastatic cutaneous nodal head and neck squamous cell carcinoma (HNSCC) have worse outcomes compared to the immunocompetent. The purpose of this study was to investigate the characteristics of the primary cutaneous squamous cell carcinoma (SCC), nodal pathology, and outcome between these 2 groups. METHODS: Analysis of a prospective database was performed. A 2:1 pooled analysis selected 46 immunocompetent patients matched with 23 immunocompromised patients. Overall survival (OS) and relapse-free survival (RFS) were calculated using the Kaplan-Meier method. RESULTS: No significant difference was found in the primary tumor characteristics between the 2 groups. In the immunocompromised group, RFS (hazard ratio [HR] 2.70; P = .01) and OS (HR 2.32; P = .04) were significantly worse. Extracapsular spread was present in 100% of the immunocompromised patients. CONCLUSION: No significant difference was identified in the primary cutaneous SCC between the immunocompetent and immunocompromised patients. Immunosuppression predicted worse outcome.
BACKGROUND: Immunocompromised patients with metastatic cutaneous nodal head and neck squamous cell carcinoma (HNSCC) have worse outcomes compared to the immunocompetent. The purpose of this study was to investigate the characteristics of the primary cutaneous squamous cell carcinoma (SCC), nodal pathology, and outcome between these 2 groups. METHODS: Analysis of a prospective database was performed. A 2:1 pooled analysis selected 46 immunocompetent patients matched with 23 immunocompromised patients. Overall survival (OS) and relapse-free survival (RFS) were calculated using the Kaplan-Meier method. RESULTS: No significant difference was found in the primary tumor characteristics between the 2 groups. In the immunocompromised group, RFS (hazard ratio [HR] 2.70; P = .01) and OS (HR 2.32; P = .04) were significantly worse. Extracapsular spread was present in 100% of the immunocompromised patients. CONCLUSION: No significant difference was identified in the primary cutaneous SCC between the immunocompetent and immunocompromised patients. Immunosuppression predicted worse outcome.
Authors: Samantha Tam; Christopher M K L Yao; Moran Amit; Mona Gajera; Xiaoning Luo; Rachel Treistman; Anshu Khanna; Mohamed Aashiq; Priyadharsini Nagarajan; Diana Bell; Adel El-Naggar; Michael Migden; Michael Wong; Bonnie Glisson; Renata Ferrarotto; Bita Esmaeli; David Rosenthal; Guojun Li; Randal S Weber; Jeffrey N Myers; Neil D Gross Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-02-01 Impact factor: 6.223
Authors: Axel Sahovaler; Rohin J Krishnan; David H Yeh; Qi Zhou; David Palma; Kevin Fung; John Yoo; Anthony Nichols; S Danielle MacNeil Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-04-01 Impact factor: 6.223